Liability unleashed? US FDA generics labeling proposal could mean lawsuits ahead
This article was originally published in SRA
Executive Summary
A proposal by the US Food and Drug Administration to allow generic drug makers to independently update their product labeling with newly-acquired safety information before regulators review those changes1,2 could expose those manufacturers to liability when patients have adverse reactions – something those companies currently are protected against under two rulings by the Supreme Court.